SG11202110036RA - Method of making lipid-encapsulated rna nanoparticles - Google Patents

Method of making lipid-encapsulated rna nanoparticles

Info

Publication number
SG11202110036RA
SG11202110036RA SG11202110036RA SG11202110036RA SG11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA
Authority
SG
Singapore
Prior art keywords
rna nanoparticles
encapsulated rna
making lipid
lipid
making
Prior art date
Application number
SG11202110036RA
Inventor
Priya Karmali
Padmanabh Chivukula
Joseph Payne
Yanjie Bao
Original Assignee
Arcturus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics Inc filed Critical Arcturus Therapeutics Inc
Publication of SG11202110036RA publication Critical patent/SG11202110036RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SG11202110036RA 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles SG11202110036RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820496P 2019-03-19 2019-03-19
PCT/US2020/023442 WO2020191103A1 (en) 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles

Publications (1)

Publication Number Publication Date
SG11202110036RA true SG11202110036RA (en) 2021-10-28

Family

ID=72515073

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110036RA SG11202110036RA (en) 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles

Country Status (11)

Country Link
US (2) US11737979B2 (en)
EP (1) EP3942050A4 (en)
JP (1) JP2022525540A (en)
KR (1) KR20220018960A (en)
CN (1) CN113840926A (en)
AU (1) AU2020241756A1 (en)
BR (1) BR112021018526A2 (en)
CA (1) CA3133858A1 (en)
IL (1) IL286424A (en)
SG (1) SG11202110036RA (en)
WO (1) WO2020191103A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
RS65449B1 (en) 2018-10-09 2024-05-31 The Univ Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related there to
CA3122080A1 (en) 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
WO2021178510A1 (en) * 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
CA3171219A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
KR20230124927A (en) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. Lipid Nanoparticles for Delivery of Nucleic Acids, and Related Methods of Use
CN112999360B (en) * 2021-04-02 2023-01-06 四川大学 Use of DMP nanoparticles in mRNA delivery
WO2023014649A1 (en) * 2021-08-02 2023-02-09 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
CA3237904A1 (en) * 2021-11-11 2023-05-19 Arcturus Therapeutics, Inc. Ionizable cationic lipids for rna delivery
CN114471217A (en) * 2022-04-02 2022-05-13 深圳市瑞吉生物科技有限公司 Convection mixing device and method for liposome synthesis
WO2024030369A1 (en) * 2022-08-01 2024-02-08 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
DE60017406T2 (en) 1999-07-15 2005-09-29 Inex Pharmaceuticals Corp., Burnaby PROCESS FOR PREPARING LIPID-CAPTAIDED THERAPEUTIC AGENTS
DK1519714T3 (en) * 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Method and apparatus for preparing liposomes
US9005654B2 (en) * 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20120021042A1 (en) 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
SG172257A1 (en) 2008-12-17 2011-07-28 Oncothyreon Inc Method of making small liposomes
WO2010148013A2 (en) * 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Lipid formulated dsrna targeting the pcsk9 gene
WO2011127255A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
US8329080B2 (en) * 2010-04-13 2012-12-11 Ricoh Company, Ltd. Conductive composition, electrophotographic belt, image forming apparatus, and method of manufacturing conductive composition
US9006417B2 (en) * 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
AU2012330819B2 (en) * 2011-11-04 2017-08-31 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
EP2895146A1 (en) * 2012-09-17 2015-07-22 BIND Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN113813899A (en) * 2013-03-14 2021-12-21 昭荣化学工业株式会社 Continuous flow reactor for synthesizing nanoparticles
CA2921161A1 (en) * 2013-09-24 2015-04-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
CN114344275A (en) 2014-07-02 2022-04-15 川斯勒佰尔公司 Encapsulation of messenger RNA
ES2949172T3 (en) 2014-07-16 2023-09-26 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
FI3221293T3 (en) 2014-11-18 2023-04-05 Arcturus Therapeutics Inc Ionizable cationic lipid for rna delivery
CN107427791B (en) 2015-03-19 2021-05-14 康涅狄格大学 System and method for continuous manufacture of liposomal pharmaceutical formulations
US10526284B2 (en) * 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery

Also Published As

Publication number Publication date
US20230398076A1 (en) 2023-12-14
EP3942050A4 (en) 2023-02-22
JP2022525540A (en) 2022-05-17
AU2020241756A1 (en) 2021-11-04
WO2020191103A1 (en) 2020-09-24
US11737979B2 (en) 2023-08-29
BR112021018526A2 (en) 2021-11-23
CN113840926A (en) 2021-12-24
KR20220018960A (en) 2022-02-15
EP3942050A1 (en) 2022-01-26
CA3133858A1 (en) 2020-09-24
US20200297634A1 (en) 2020-09-24
IL286424A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
IL286424A (en) Method of making lipid-encapsulated rna nanoparticles
EP3633075A4 (en) Metal porous body and method for producing metal porous body
EP3463648A4 (en) Core/shell catalyst particles and method of manufacture
EP3786097A4 (en) Elevator, suspension body therefor, and method for producing same
EP3703886A4 (en) Metal nanoparticles and methods of making same
EP3450570A4 (en) Method for evaluating, in vivo, activity of rna-guided nuclease in high-throughput manner
EP3115483A4 (en) Porous metal body and method for producing porous metal body
EP3405304B8 (en) Gold nanoparticles and ecological method of production
EP3421610A4 (en) METHOD FOR EVALUATING QUALITY OF miRNA DERIVED FROM BODY FLUID
EP3271288A4 (en) Metal oxide particles and method of producing thereof
EP3307679A4 (en) Sodium transition metal silicate and method of forming same
EP3765645A4 (en) Method of aluminum-scandium alloy production
EP3766571A4 (en) Hollow particles, method for producing same, and usage of same
GB201804594D0 (en) Bonegraft substituteand method of manufacture
EP4081687A4 (en) Method of construction
GB201709827D0 (en) Method of making colloidal metal nanoparticles
EP3262936A4 (en) Oily suspension composition and method for producing same
GB201720829D0 (en) Aerofoil and method of manufacture
GB201802839D0 (en) Method of manufacture
EP3347328A4 (en) Method of forming porous ceramic particles
EP3467014A4 (en) Method of producing porous body
GB2578185B (en) Method of making colloidal platinum nanoparticles
SG11202101056RA (en) HIGH-Mn STEEL AND METHOD OF PRODUCING SAME
EP3326384A4 (en) Loudspeaker and method of its manufacture
EP3615085A4 (en) Rna nanostructures, methods of making, and uses thereof